Which has stronger earnings and valuation, LFWD or PAVM?

PAVmed has lower revenue, but higher earnings than Lifeward. Lifeward is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lifeward $22.03M 0.90 -$19.91M -$19.66 N/A PAVmed $70K 67.71 $400K -$37.40 N/A

Is LFWD or PAVM more profitable?

Lifeward has a net margin of -123.66% compared to PAVmed's net margin of -21,914.12%. PAVmed's return on equity of -146.19% beat Lifeward's return on equity. Company Net Margins Return on Equity Return on Assets Lifeward -123.66% -243.14% -97.39% PAVmed -21,914.12% -146.19% -18.39%

Does the media favor LFWD or PAVM?

In the previous week, Lifeward and Lifeward both had 2 articles in the media. Lifeward's average media sentiment score of 0.94 beat PAVmed's score of 0.93 indicating that Lifeward is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifeward 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PAVmed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RVP or PAVM?

PAVmed has a consensus target price of $56.00, indicating a potential upside of 1,081.43%. Given PAVmed's stronger consensus rating and higher probable upside, analysts clearly believe PAVmed is more favorable than Retractable Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Retractable Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PAVmed 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer PAVM or TMDIF?

PAVmed presently has a consensus target price of $56.00, indicating a potential upside of 1,081.43%. Given PAVmed's stronger consensus rating and higher probable upside, analysts clearly believe PAVmed is more favorable than Titan Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PAVmed 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, PAVM or TMDIF?

Titan Medical has higher revenue and earnings than PAVmed. PAVmed is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PAVmed $70K 67.71 $400K -$37.40 N/A Titan Medical $17.63M 0.74 $6.95M $0.05 2.30

Is PAVM or TMDIF more profitable?

Titan Medical has a net margin of 0.00% compared to PAVmed's net margin of -21,914.12%. Titan Medical's return on equity of -82.31% beat PAVmed's return on equity. Company Net Margins Return on Equity Return on Assets PAVmed -21,914.12% -146.19% -18.39% Titan Medical N/A -82.31% -51.47%

Do analysts recommend PAVM or ZJYL?

PAVmed currently has a consensus target price of $56.00, indicating a potential upside of 1,081.43%. Given PAVmed's stronger consensus rating and higher probable upside, equities research analysts clearly believe PAVmed is more favorable than Jin Medical International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PAVmed 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Jin Medical International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, PAVM or ZJYL?

Jin Medical International has higher revenue and earnings than PAVmed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PAVmed $70K 67.71 $400K -$37.40 N/A Jin Medical International $20.69M 0.65 $1.19M N/A N/A

Does the media prefer PAVM or ZJYL?

In the previous week, Jin Medical International had 2 more articles in the media than PAVmed. MarketBeat recorded 4 mentions for Jin Medical International and 2 mentions for PAVmed. PAVmed's average media sentiment score of 0.93 beat Jin Medical International's score of 0.50 indicating that PAVmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PAVmed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jin Medical International 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

PAVmed (PAVM) Competitors

$4.74 +0.20 (+4.41%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$4.89 +0.15 (+3.16%)

As of 07/24/2026 07:34 PM Eastern

Compare

PAVM vs. LFWD, RVP, TMDIF, NMTC, and ZJYL

Should you buy PAVmed stock or one of its competitors? MarketBeat compares PAVmed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PAVmed include Lifeward (LFWD), Retractable Technologies (RVP), Titan Medical (TMDIF), NeuroOne Medical Technologies (NMTC), and Jin Medical International (ZJYL). These companies are all part of the "medical equipment" industry.

How does PAVmed compare to Lifeward?

Lifeward (NASDAQ:LFWD) and PAVmed (NASDAQ:PAVM) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

PAVmed has lower revenue, but higher earnings than Lifeward. Lifeward is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifeward	$22.03M	0.90	-$19.91M	-$19.66	N/A
PAVmed	$70K	67.71	$400K	-$37.40	N/A

In the previous week, Lifeward and Lifeward both had 2 articles in the media. Lifeward's average media sentiment score of 0.94 beat PAVmed's score of 0.93 indicating that Lifeward is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifeward	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PAVmed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lifeward currently has a consensus target price of $10.00, suggesting a potential upside of 41.84%. PAVmed has a consensus target price of $56.00, suggesting a potential upside of 1,081.43%. Given PAVmed's stronger consensus rating and higher possible upside, analysts clearly believe PAVmed is more favorable than Lifeward.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifeward	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lifeward has a net margin of -123.66% compared to PAVmed's net margin of -21,914.12%. PAVmed's return on equity of -146.19% beat Lifeward's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifeward	-123.66%	-243.14%	-97.39%
PAVmed	-21,914.12%	-146.19%	-18.39%

Lifeward has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market. Comparatively, PAVmed has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

26.8% of Lifeward shares are held by institutional investors. Comparatively, 19.9% of PAVmed shares are held by institutional investors. 1.5% of Lifeward shares are held by company insiders. Comparatively, 13.4% of PAVmed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

PAVmed beats Lifeward on 9 of the 14 factors compared between the two stocks.

How does PAVmed compare to Retractable Technologies?

Retractable Technologies (NYSE:RVP) and PAVmed (NASDAQ:PAVM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

PAVmed has a consensus target price of $56.00, indicating a potential upside of 1,081.43%. Given PAVmed's stronger consensus rating and higher probable upside, analysts clearly believe PAVmed is more favorable than Retractable Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Retractable Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, PAVmed had 2 more articles in the media than Retractable Technologies. MarketBeat recorded 2 mentions for PAVmed and 0 mentions for Retractable Technologies. PAVmed's average media sentiment score of 0.93 beat Retractable Technologies' score of 0.00 indicating that PAVmed is being referred to more favorably in the news media.

Company	Overall Sentiment
Retractable Technologies	Neutral
PAVmed	Positive

PAVmed has lower revenue, but higher earnings than Retractable Technologies. Retractable Technologies is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Retractable Technologies	$37.15M	0.55	-$7.01M	-$0.21	N/A
PAVmed	$70K	67.71	$400K	-$37.40	N/A

Retractable Technologies has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, PAVmed has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

Retractable Technologies has a net margin of -41.11% compared to PAVmed's net margin of -21,914.12%. Retractable Technologies' return on equity of -17.15% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Retractable Technologies	-41.11%	-17.15%	-9.33%
PAVmed	-21,914.12%	-146.19%	-18.39%

7.6% of Retractable Technologies shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 59.5% of Retractable Technologies shares are owned by insiders. Comparatively, 13.4% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

PAVmed beats Retractable Technologies on 9 of the 16 factors compared between the two stocks.

How does PAVmed compare to Titan Medical?

PAVmed (NASDAQ:PAVM) and Titan Medical (NASDAQ:TMDIF) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

Titan Medical has a net margin of 0.00% compared to PAVmed's net margin of -21,914.12%. Titan Medical's return on equity of -82.31% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAVmed	-21,914.12%	-146.19%	-18.39%
Titan Medical	N/A	-82.31%	-51.47%

PAVmed has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Titan Medical has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

PAVmed presently has a consensus target price of $56.00, indicating a potential upside of 1,081.43%. Given PAVmed's stronger consensus rating and higher probable upside, analysts clearly believe PAVmed is more favorable than Titan Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Titan Medical has higher revenue and earnings than PAVmed. PAVmed is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$70K	67.71	$400K	-$37.40	N/A
Titan Medical	$17.63M	0.74	$6.95M	$0.05	2.30

In the previous week, PAVmed had 2 more articles in the media than Titan Medical. MarketBeat recorded 2 mentions for PAVmed and 0 mentions for Titan Medical. PAVmed's average media sentiment score of 0.93 beat Titan Medical's score of 0.00 indicating that PAVmed is being referred to more favorably in the media.

Company	Overall Sentiment
PAVmed	Positive
Titan Medical	Neutral

19.9% of PAVmed shares are owned by institutional investors. Comparatively, 0.0% of Titan Medical shares are owned by institutional investors. 13.4% of PAVmed shares are owned by insiders. Comparatively, 0.0% of Titan Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

PAVmed beats Titan Medical on 9 of the 16 factors compared between the two stocks.

How does PAVmed compare to NeuroOne Medical Technologies?

PAVmed (NASDAQ:PAVM) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

PAVmed has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

PAVmed presently has a consensus price target of $56.00, suggesting a potential upside of 1,081.43%. NeuroOne Medical Technologies has a consensus price target of $11.67, suggesting a potential upside of 514.04%. Given PAVmed's higher possible upside, analysts plainly believe PAVmed is more favorable than NeuroOne Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

PAVmed has higher earnings, but lower revenue than NeuroOne Medical Technologies. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$70K	67.71	$400K	-$37.40	N/A
NeuroOne Medical Technologies	$12.10M	1.37	-$3.61M	-$0.85	N/A

In the previous week, PAVmed and PAVmed both had 2 articles in the media. NeuroOne Medical Technologies' average media sentiment score of 1.44 beat PAVmed's score of 0.93 indicating that NeuroOne Medical Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
PAVmed	Positive
NeuroOne Medical Technologies	Positive

19.9% of PAVmed shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 13.4% of PAVmed shares are held by company insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

NeuroOne Medical Technologies has a net margin of -68.35% compared to PAVmed's net margin of -21,914.12%. NeuroOne Medical Technologies' return on equity of -99.43% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAVmed	-21,914.12%	-146.19%	-18.39%
NeuroOne Medical Technologies	-68.35%	-99.43%	-70.40%

Summary

PAVmed and NeuroOne Medical Technologies tied by winning 7 of the 14 factors compared between the two stocks.

How does PAVmed compare to Jin Medical International?

PAVmed (NASDAQ:PAVM) and Jin Medical International (NASDAQ:ZJYL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

PAVmed has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Jin Medical International has a beta of 7.34, suggesting that its stock price is 634% more volatile than the broader market.

Jin Medical International has a net margin of 0.00% compared to PAVmed's net margin of -21,914.12%. Jin Medical International's return on equity of 0.00% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAVmed	-21,914.12%	-146.19%	-18.39%
Jin Medical International	N/A	N/A	N/A

Jin Medical International has higher revenue and earnings than PAVmed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$70K	67.71	$400K	-$37.40	N/A
Jin Medical International	$20.69M	0.65	$1.19M	N/A	N/A

In the previous week, Jin Medical International had 2 more articles in the media than PAVmed. MarketBeat recorded 4 mentions for Jin Medical International and 2 mentions for PAVmed. PAVmed's average media sentiment score of 0.93 beat Jin Medical International's score of 0.50 indicating that PAVmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PAVmed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jin Medical International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PAVmed currently has a consensus target price of $56.00, indicating a potential upside of 1,081.43%. Given PAVmed's stronger consensus rating and higher probable upside, equities research analysts clearly believe PAVmed is more favorable than Jin Medical International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Jin Medical International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

19.9% of PAVmed shares are owned by institutional investors. 13.4% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

PAVmed and Jin Medical International tied by winning 7 of the 14 factors compared between the two stocks.

Get PAVmed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PAVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PAVM vs. The Competition

Export

Metric	PAVmed	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.52M	$7.30B	$6.87B	$12.26B
Dividend Yield	N/A	1.33%	2.67%	9.79%
P/E Ratio	-0.13	48.63	27.14	23.64
Price / Sales	67.71	96.88	517.08	89.45
Price / Cash	N/A	25.71	50.54	59.64
Price / Book	-1.96	6.73	10.28	6.07
Net Income	$400K	$162.27M	$3.60B	$331.99M
7 Day Performance	-20.20%	-5.05%	-1.27%	-0.63%
1 Month Performance	8.97%	-5.86%	-0.37%	-2.00%
1 Year Performance	-72.84%	-2.88%	18.30%	13.62%

PAVmed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PAVM PAVmed	3.2776 of 5 stars	$4.74 +4.4%	$56.00 +1,081.4%	-73.0%	$4.52M	$70K	N/A	90
LFWD Lifeward	1.9258 of 5 stars	$7.25 -4.0%	$10.00 +37.9%	-28.9%	$20.40M	$20.92M	N/A	60	Gap Up
RVP Retractable Technologies	N/A	$0.68 -1.4%	N/A	-3.6%	$20.36M	$37.15M	N/A	240
TMDIF Titan Medical	N/A	$0.16 +1.7%	N/A	-66.1%	$18.32M	$17.63M	N/A	50	Gap Down
NMTC NeuroOne Medical Technologies	3.1654 of 5 stars	$2.05 -5.1%	$11.67 +469.1%	-64.9%	$17.84M	$12.10M	N/A	20	Negative News Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PAVM) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PAVmed (PAVM) Competitors

PAVM vs. LFWD, RVP, TMDIF, NMTC, and ZJYL

How does PAVmed compare to Lifeward?

Summary

How does PAVmed compare to Retractable Technologies?

Summary

How does PAVmed compare to Titan Medical?

Summary

How does PAVmed compare to NeuroOne Medical Technologies?

Summary

How does PAVmed compare to Jin Medical International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAVM vs. The Competition

PAVmed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PAVmed (PAVM) Competitors

PAVM vs. LFWD, RVP, TMDIF, NMTC, and ZJYL

How does PAVmed compare to Lifeward?

Which has stronger earnings and valuation, LFWD or PAVM?

Does the media favor LFWD or PAVM?

Do analysts recommend LFWD or PAVM?

Is LFWD or PAVM more profitable?

Which has more risk & volatility, LFWD or PAVM?

Do institutionals and insiders have more ownership in LFWD or PAVM?

Summary

How does PAVmed compare to Retractable Technologies?

Do analysts prefer RVP or PAVM?

Does the media refer more to RVP or PAVM?

Which has stronger earnings & valuation, RVP or PAVM?

Which has more risk & volatility, RVP or PAVM?

Is RVP or PAVM more profitable?

Do insiders and institutionals believe in RVP or PAVM?

Summary

How does PAVmed compare to Titan Medical?

Is PAVM or TMDIF more profitable?

Which has more volatility and risk, PAVM or TMDIF?

Do analysts prefer PAVM or TMDIF?

Which has higher earnings and valuation, PAVM or TMDIF?

Does the media refer more to PAVM or TMDIF?

Do institutionals and insiders believe in PAVM or TMDIF?

Summary

How does PAVmed compare to NeuroOne Medical Technologies?

Which has more volatility and risk, PAVM or NMTC?

Do analysts recommend PAVM or NMTC?

Which has preferable earnings & valuation, PAVM or NMTC?

Does the media refer more to PAVM or NMTC?

Do insiders & institutionals have more ownership in PAVM or NMTC?

Is PAVM or NMTC more profitable?

Summary

How does PAVmed compare to Jin Medical International?

Which has more volatility and risk, PAVM or ZJYL?

Is PAVM or ZJYL more profitable?

Which has higher valuation & earnings, PAVM or ZJYL?

Does the media prefer PAVM or ZJYL?

Do analysts recommend PAVM or ZJYL?

Do insiders & institutionals believe in PAVM or ZJYL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAVM vs. The Competition

PAVmed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools